Literature DB >> 25143000

MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth.

Junfeng Wang1, Fang Yu, Xuemei Jia, Stephen Iwanowycz, Yuzhen Wang, Shiang Huang, Walden Ai, Daping Fan.   

Abstract

Immune cells in tumor microenvironment play a prominent role in tumor progression and metastasis. MicroRNA-155 (miR-155) represents an important player in innate and adaptive immunity by regulating differentiation, maturation and activation of macrophages, dendritic cells, B cells and T cells. However, the role of miR-155 expression in immune cells in solid tumor development is less elucidated. Our current study showed that both B16-F10 melanoma and Lewis lung carcinoma tumors grew much faster in bic/miR-155 knockout (miR-155(-/-) ) mice along with an increase of myeloid-derived suppressor cells (MDSCs) accumulation in tumors, compared to that in wild-type mice. Bone marrow transplantation study showed that bone marrow miR-155 deficiency could replicate the above tumor-promoting phenotype. In vitro study demonstrated that tumor-infiltrating miR-155(-/-) MDSCs showed greater migration ability and expressed higher level of multiple chemokines. Furthermore, we found that the level of HIF-1α, a direct target of miR-155, was increased in miR-155 deficient MDSCs, and that the increased HIF-1α upregulated CXCL1, CXCL3 and CXCL8 expression in MDSCs, contributing to the enhanced recruitment of miR-155(-/-) MDSCs to the tumors. Moreover, miR-155(-/-) MDSCs showed enhanced immunosuppressive and pro-angiogenic capacities. Taken together, our study, for the first time, demonstrated that miR-155 deficiency promoted solid tumor growth through increasing the recruitment of MDSCs to tumor microenvironment and enhancing the tumor-promoting functions of the recruited MDSCs. Thus, upregulating miR-155 expression in MDSCs may be developed as a therapeutic approach to halt tumor development.
© 2014 UICC.

Entities:  

Keywords:  HIF-1α; MDSCs; chemokines; microRNA-155; tumor growth

Mesh:

Substances:

Year:  2014        PMID: 25143000      PMCID: PMC4289468          DOI: 10.1002/ijc.29151

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  49 in total

Review 1.  The inflammatory tumor microenvironment and its impact on cancer development.

Authors:  Karin E de Visser; Lisa M Coussens
Journal:  Contrib Microbiol       Date:  2006

Review 2.  Chronic inflammation and cancer: suppressing the suppressors.

Authors:  Michal Baniyash; Moshe Sade-Feldman; Julia Kanterman
Journal:  Cancer Immunol Immunother       Date:  2013-08-29       Impact factor: 6.968

Review 3.  Recruitment of monocytes/macrophages in different tumor microenvironments.

Authors:  Heon-Woo Lee; Hyun-Jung Choi; Sang-Jun Ha; Kyung-Tae Lee; Young-Guen Kwon
Journal:  Biochim Biophys Acta       Date:  2012-12-31

4.  Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia.

Authors:  Sensen Lin; Shuying Wan; Li Sun; Jialiang Hu; Dongdong Fang; Renping Zhao; Shengtao Yuan; Luyong Zhang
Journal:  Cancer Sci       Date:  2012-04-12       Impact factor: 6.716

5.  MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development.

Authors:  Ryan M O'Connell; Daniel Kahn; William S J Gibson; June L Round; Rebecca L Scholz; Aadel A Chaudhuri; Melissa E Kahn; Dinesh S Rao; David Baltimore
Journal:  Immunity       Date:  2010-09-30       Impact factor: 31.745

6.  MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.

Authors:  Pingyu Zhang; Katelynn Bill; Juehui Liu; Eric Young; Tingsheng Peng; Svetlana Bolshakov; Aviad Hoffman; Yechun Song; Elizabeth G Demicco; Dolores Lopez Terrada; Chad J Creighton; Matthew L Anderson; Alexander J Lazar; George G Calin; Raphael E Pollock; Dina Lev
Journal:  Cancer Res       Date:  2012-02-20       Impact factor: 12.701

7.  Tumor microenvironment and myeloid-derived suppressor cells.

Authors:  Viktor Umansky; Alexandra Sevko
Journal:  Cancer Microenviron       Date:  2012-12-16

8.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

9.  Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma.

Authors:  Mengzi Zhang; Xiaoju Zhou; Bo Wang; Bryant C Yung; Ly J Lee; Kalpana Ghoshal; Robert J Lee
Journal:  J Control Release       Date:  2013-04-06       Impact factor: 9.776

10.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion.

Authors:  Rose Du; Kan V Lu; Claudia Petritsch; Patty Liu; Ruth Ganss; Emmanuelle Passegué; Hanqiu Song; Scott Vandenberg; Randall S Johnson; Zena Werb; Gabriele Bergers
Journal:  Cancer Cell       Date:  2008-03       Impact factor: 31.743

View more
  50 in total

1.  Transcriptional factor EB regulates macrophage polarization in the tumor microenvironment.

Authors:  Liang Fang; Johnie Hodge; Fatma Saaoud; Junfeng Wang; Stephen Iwanowycz; Yuzhen Wang; Yvonne Hui; Trent D Evans; Babak Razani; Daping Fan
Journal:  Oncoimmunology       Date:  2017-04-20       Impact factor: 8.110

2.  Regulating Tumor Myeloid-Derived Suppressor Cells by MicroRNAs.

Authors:  Siqi Chen; Yi Zhang; Timothy M Kuzel; Bin Zhang
Journal:  Cancer Cell Microenviron       Date:  2015

3.  Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.

Authors:  Thomas B Huffaker; Soh-Hyun Lee; William W Tang; Jared A Wallace; Margaret Alexander; Marah C Runtsch; Dane K Larsen; Jacob Thompson; Andrew G Ramstead; Warren P Voth; Ruozhen Hu; June L Round; Matthew A Williams; Ryan M O'Connell
Journal:  J Biol Chem       Date:  2017-09-14       Impact factor: 5.157

Review 4.  MicroRNA heterogeneity in melanoma progression.

Authors:  Anita Thyagarajan; Kenneth Y Tsai; Ravi P Sahu
Journal:  Semin Cancer Biol       Date:  2019-06-01       Impact factor: 15.707

5.  MicroRNA-365 inhibits growth, invasion and metastasis of malignant melanoma by targeting NRP1 expression.

Authors:  Juanjuan Bai; Zhongling Zhang; Xing Li; Huifan Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  MicroRNA-155 expression inversely correlates with pathologic stage of gastric cancer and it inhibits gastric cancer cell growth by targeting cyclin D1.

Authors:  Zhijun Ma; Yulan Ma; Qinghua Xia; Yong Li; Ruidong Li; Weilong Chang; Jinhuang Chen; Zhengwei Leng; Kaixiong Tao
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-08       Impact factor: 4.553

7.  Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages.

Authors:  Stephen Iwanowycz; Junfeng Wang; Johnie Hodge; Yuzhen Wang; Fang Yu; Daping Fan
Journal:  Mol Cancer Ther       Date:  2016-05-18       Impact factor: 6.261

Review 8.  The immunobiology of myeloid-derived suppressor cells in cancer.

Authors:  Morteza Motallebnezhad; Farhad Jadidi-Niaragh; Elmira Safaie Qamsari; Salman Bagheri; Tohid Gharibi; Mehdi Yousefi
Journal:  Tumour Biol       Date:  2015-11-26

9.  MicroRNA-155 deletion promotes tumorigenesis in the azoxymethane-dextran sulfate sodium model of colon cancer.

Authors:  Kandy T Velázquez; Reilly T Enos; Jamie L McClellan; Taryn L Cranford; Ioulia Chatzistamou; Udai P Singh; Mitzi Nagarkatti; Prakash S Nagarkatti; Daping Fan; E Angela Murphy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-01-07       Impact factor: 4.052

10.  Melanoma exosomes promote mixed M1 and M2 macrophage polarization.

Authors:  Gina T Bardi; Mary Ann Smith; Joshua L Hood
Journal:  Cytokine       Date:  2018-02-17       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.